Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Breast cancer

    Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options
    Special Populations

    Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options

    Healthcare providers are less likely to talk to Black patients with metastatic breast cancer about opportunities to enroll in clinical trials than they are with patients from other racial or ethnic backgrounds, researchers reported at the 2022 ASCO Annual Meeting.

    February 01, 2023
    FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Variant Advanced or Metastatic Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Elacestrant for ER-Positive, HER2-Negative, ESR1-Variant Advanced or Metastatic Breast Cancer

    On January 27, 2023, the U.S. Food and Drug Administration approved elacestrant (Orserdu®) for postmenopausal women or adult men with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-variant advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

    January 31, 2023
    Cancer Hits Home for NCI Director Bertagnolli
    National Cancer Institute (NCI)

    Cancer Hits Home for NCI Director Bertagnolli

    In a December 2022 statement, Monica M. Bertagnolli, MD, National Cancer Institute director,  announced that she was diagnosed with hormone receptor-positive, HER2-negative breast cancer and that her prognosis is favorable. She said she is enrolled in a clinical trial centered around her diagnosis to contribute to the cancer knowledge base and advance care.

    January 23, 2023
    Biomarkers Are Associated With Frailty After Chemo for Breast Cancer
    Breast cancer

    Biomarkers Are Associated With Frailty After Chemo for Breast Cancer

    High levels of interleukin-6 (IL-6) and C-reactive protein before chemotherapy for breast cancer may predict a patient’s propensity to develop clinical decline and frailty after treatment, according to study findings that researchers reported in the Journal of Clinical Oncology.

    November 09, 2022
    What Is HER2-Low Breast Cancer?
    Breast cancer

    What Is HER2-Low Breast Cancer?

    Human epidermal growth factor receptor 2 (HER2) proteins are involved in normal cellular growth and are found on the surface of all breast cells. Approximately 20% of breast cancers are HER2 positive, meaning they have high levels of HER2 protein, and those cancers typically grow and metastasize more quickly than other types of breast cancer.

    October 07, 2022
    Tumor-Infiltrating Lymphocytes Activate Immune Response to Metastatic Breast Cancer
    Breast cancer

    Tumor-Infiltrating Lymphocytes Activate Immune Response to Metastatic Breast Cancer

    More than two-thirds of patients with hormone receptor–positive metastatic breast cancer respond to personalized immunotherapy with tumor-infiltrating lymphocytes and more than half of those treated experience measurable tumor shrinkage, according to study findings published in the Journal of Clinical Oncology.

    October 05, 2022
    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Low Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for HER2-Low Breast Cancer

    On August 5, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for use in adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH‑) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.

    August 08, 2022
    FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki for Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Regular Approval to Fam-Trastuzumab Deruxtecan-Nxki for Breast Cancer

    On May 4, 2022, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2–based regimen in the metastatic setting as well as those in the neoadjuvant or adjuvant setting who developed disease recurrence during or within six months of completing therapy.

    May 06, 2022
    Breast-Conserving Surgery Leads to Better QOL for Young Breast Cancer Survivors
    Breast cancer

    Breast-Conserving Surgery Leads to Better QOL for Young Breast Cancer Survivors

    Patients younger than 40 who elected to have breast-conserving surgery instead of mastectomy to remove breast cancer reported having better quality of life (QOL) more than five years after diagnosis, according to study findings reported in JAMA Surgery.

    April 13, 2022
    FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Olaparib for Adjuvant Treatment of High-Risk Early Breast Cancer

    On March 11, 2022, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza®) for adult patients with deleterious or suspected deleterious germline BRCA variant (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients are selected for therapy based on an FDA-approved companion diagnostic for olaparib.

    March 18, 2022
    Genetic Disorder Reference Sheet: PALB2
    Genetics & genomics

    Genetic Disorder Reference Sheet: PALB2

    PALB2 refers to partner and localizer of BRCA2. The gene was isolated in 2007 and is the third most common gene associated with breast cancer risk. Both men and women are at increased risk for developing multiple cancers if they have a pathogenic PALB2 variant (see sidebar).

    March 15, 2022
    Specialized Risk Calculator May Reduce Disparities for Black Patients With Breast Cancer
    Cancer health disparities

    Specialized Risk Calculator May Reduce Disparities for Black Patients With Breast Cancer

    A new risk model tailored for Black patients predicts their risk of developing breast cancer as accurately as current models for White patients, researchers reported in the Journal of Clinical Oncology. Because Black patients are more likely to be younger at diagnosis, present with aggressive or advanced cancer, and die from the disease than other racial and ethnic groups, using the new model to personalize prevention and screening recommendations may reduce those disparities.

    March 02, 2022
    How Liquid Biopsies Are Used in Cancer Treatment Selection
    Cancer treatments

    How Liquid Biopsies Are Used in Cancer Treatment Selection

    Biomarker testing is an essential tool when choosing the right treatment for many advanced solid cancers. However, tissue-based testing may take weeks to get results with a chance that not enough tissue was collected to complete the entire biomarker panel. Blood draw–based liquid biopsies may be a useful alternative to identify a tumor’s biomarker details and can be performed by testing for circulating tumor DNA (ctDNA).

    February 03, 2022
    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
    Cancer research

    Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer

    Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.

    February 02, 2022
    FDA Approves Abemaciclib With Endocrine Therapy for Early Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Abemaciclib With Endocrine Therapy for Early Breast Cancer

    On October 12, 2021, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio®) with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk for recurrence and a Ki-67 score ≥ 20%, as determined by an FDA-approved test. This is the first CDK4/6 inhibitor approved for adjuvant treatment of breast cancer.  

    October 13, 2021
    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy
    Drug Reference Sheet

    Oncology Drug Reference Sheet: Sacituzumab Govitecan-Hziy

    Initially marketed in April 2020 for treatment of adults with metastatic triple negative breast cancer, sacituzumab govitecan-hziy (Trodelvy®) received an additional approval in 2021 for the treatment of patients with locally advanced or metastatic urothelial cancer with prior treatments.

    September 28, 2021
    The Case of the Triple-Negative Breast Cancer Targeted Treatment
    Breast cancer

    The Case of the Triple-Negative Breast Cancer Targeted Treatment

    Ophelia is a 42-year-old patient who has been diagnosed with triple-negative breast cancer (TNBC). She completed neoadjuvant chemotherapy with dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel and carboplatin. Her postsurgical pathology shows residual disease in the tumor (3.5 cm down from 4 cm) and 12 out of 18 lymph nodes that are positive for cancer. Ophelia tells you that she is very discouraged and expected a better treatment outcome.

    September 21, 2021
    U.S. Senators Introduce Metastatic Breast Cancer Access to Care Act
    Breast cancer

    U.S. Senators Introduce Metastatic Breast Cancer Access to Care Act

    In April 2021, U.S. Senators Chris Murphy (D-CT) and Joni Ernst (R-IA) introduced the Metastatic Breast Cancer Access to Care Act, legislation that would waive the five-month waiting period for social security disability insurance (SSDI) and the 24-month waiting period for eligible Medicare benefits.

    August 16, 2021
    FDA Approves Pembrolizumab for High-Risk, Early-Stage, Triple-Negative Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for High-Risk, Early-Stage, Triple-Negative Breast Cancer

    On July 26, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment and continued as a single agent as adjuvant treatment after surgery. 

    July 27, 2021
    Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer
    Research

    Imaging Test Identifies Treatment Choices for ER-Positive Breast Cancer

    Using positron-emission tomography with a radioactive tracer identifies levels of progesterone receptor in patients with estrogen receptor-positive breast cancer, researchers reported in Nature Communications. The diagnostic tool would help clinicians determine which patients are most likely to respond to hormone therapies for breast cancer.

    May 27, 2021
    Breast cancer

    HER2 Status Has Implications for Breast Cancer Treatment and Nursing Care

    Breast cancer is classified by several factors, including the presence of human epidermal growth factor receptor 2 (HER2), a type of growth-promoting protein found on the surface of cells. All breast cells have HER2 receptors, but some breast cancers have more HER2 receptors than normal, which may promote tumor growth. About 60% of breast cancers have some level of HER2 expression, and approximately one in five patients has high levels of the HER2 protein, which is considered HER2-positive.

    April 22, 2021
    FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer
    Clinical practice

    FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer

    On April 7, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy®) for patients with unresectable locally advanced or metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of which for metastatic disease.

    April 08, 2021
    FDA Issues Safety Communication for ADM Products Used in Implant-Based Breast Reconstruction
    Clinical practice

    FDA Issues Safety Communication for ADM Products Used in Implant-Based Breast Reconstruction

    On March 31, 2021, the U.S. Food and Drug Administration (FDA) issued a safety communication informing patients, caregivers, and healthcare providers that certain acellular dermal matrix (ADM) products used in implant-based breast reconstruction may have a higher chance for complications or problems.

    April 07, 2021
    Manage Adverse Events From PI3K Inhibitors for Breast Cancer
    Breast cancer

    Manage Adverse Events From PI3K Inhibitors for Breast Cancer

    In 2019, PI3K inhibitors became a new treatment option for postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer with the U.S. Food and Drug Administration’s approval of alpelisib in combination with fulvestrant. Although alpelisib remains the only PI3K inhibitor approved today, others are in clinical trials, and the new class of agents has a unique safety profile.

    March 09, 2021
    Nursing Considerations for Breast Cancer Survivorship Care
    Breast cancer

    Nursing Considerations for Breast Cancer Survivorship Care

    More than 3.5 million people in the United States are living with a breast cancer diagnosis. Despite their large number, patients often report they do not receive appropriate follow-up care after completing treatment—and the situation is worsening, with pandemic-related delays in care affecting approximately half of breast cancer survivors.

    January 28, 2021
    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer
    Cancer treatments

    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer

    On December 16, 2020, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza™) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease.

    December 18, 2020
    FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC

    On November 13, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score [CPS] ≥ 10) as determined by an FDA-approved test. FDA also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for selecting patients with TNBC for pembrolizumab.

    November 16, 2020
    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations
    Breast cancer

    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations

    In the United States, breast cancer is the most commonly diagnosed cancer in women. One in eight women will develop invasive disease in their lifetime with approximately 270,00 new cases diagnosed in the United States in 2019. Caucasian women have the highest incidence rate, whereas African American women are most likely to die from the disease. The five-year survival rate is 91%, with an estimated 3.8 million breast cancer survivors living in the United States.

    October 15, 2020
    FDA Rejects Atezolizumab in Combination With Paclitaxel as Treatment for Breast Cancer 
    U.S. Food and Drug Administration (FDA)

    FDA Rejects Atezolizumab in Combination With Paclitaxel as Treatment for Breast Cancer 

    On September 8, 2020, the U.S. Food and Drug Administration (FDA) announced it did not approve atezolizumab (Tecentriq®) in combination with paclitaxel for treatment of breast cancer after a clinical trial studying the use of atezolizumab and paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) showed the drug combination did not work to treat the disease.   

    September 09, 2020
    ACA Led to Higher Rates of Early Breast Cancer Diagnoses
    Research

    ACA Led to Higher Rates of Early Breast Cancer Diagnoses

    Thanks to expanded Medicaid coverage from the Affordable Care Act (ACA), women diagnosed with breast cancer—and in particular, African American women who are more likely to experience breast cancer disparities—are getting their cancers found at earlier stages, according to researchers. The study findings were reported in JAMA Surgery.

    August 19, 2020
    Insulin Resistance May Explain Racial Disparity in Breast Cancer
    Cancer research

    Insulin Resistance May Explain Racial Disparity in Breast Cancer

    Black women with breast cancer typically have a worse prognosis than white women, and the results of a new study suggest that insulin resistance may be a factor in the disparity. Findings from the study were reported in Breast Cancer Research.

    July 22, 2020
    Dietary Supplements May Affect Breast Cancer Chemo Outcomes
    Chemotherapy

    Dietary Supplements May Affect Breast Cancer Chemo Outcomes

    Antioxidant supplements are associated with increased disease recurrence and statistically nonsignificant increased risk of mortality in patients with breast cancer who were receiving cyclophosphamide, doxorubicin, and paclitaxel, according to findings from a study reported in the Journal of Clinical Oncology.

    May 13, 2020
    FDA Grants Accelerated Approval to Sacituzumab Govitecan-Hziy for Metastatic Triple-Negative Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Sacituzumab Govitecan-Hziy for Metastatic Triple-Negative Breast Cancer

    April 23, 2020
    FDA Approves First New Drug Under International Collaboration, a Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer 
    U.S. Food and Drug Administration (FDA)

    FDA Approves First New Drug Under International Collaboration, a Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer 

    On April 17, 2020, as part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa™) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery or have spread to other parts of the body, including the brain, and who have received one or more prior treatments. 

    April 20, 2020
    New Treatments Show Promise for Metastatic HER2-Positive Breast Cancer
    Breast cancer

    New Treatments Show Promise for Metastatic HER2-Positive Breast Cancer

    Two new drugs in clinical trials are extending survival for women with metastatic HER2-positive breast cancer that had progressed with previous treatment. One of the drugs was effective for brain metastasis, which is particularly difficult to treat. Results from both studies were reported in the New England Journal of Medicine. 

    April 15, 2020
    Genomic Classifier Predicts Breast Cancer Radiation Benefit, Recurrence Risk
    Breast cancer

    Genomic Classifier Predicts Breast Cancer Radiation Benefit, Recurrence Risk

    The Adjuvant Radiotherapy Intensification Classifier (ARTIC) predicts which women with early-stage breast cancer will benefit the most from radiotherapy, as well as their risk for locoregional recurrence after radiation, researchers reported in study findings published in the Journal of Clinical Oncology. 

    March 30, 2020
    Latinas’ Breast Cancer Genetic Disparities Require More Focused Counseling and Testing
    Breast cancer

    Latinas’ Breast Cancer Genetic Disparities Require More Focused Counseling and Testing

    Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in Latina women. Compared to all patients with breast cancer, Latinas are the second most common ethnic group to carry BRCA1 deleterious mutations, after Ashkenazi Jewish women. However, Latinas are less likely to receive genetic counseling education, referrals, and testing services and have the least awareness of genetic testing compared to non-Hispanic whites and other minority populations. Research indicates that despite their low awareness, Latinas have high interest in participating in genetic counseling and testing. 

    March 27, 2020
    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer

    On February 25, 2020, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlyn®) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

    February 26, 2020
    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up
    Treatments

    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up

    January 22, 2020
    Breast Cancer Is More Fatal in Men Than Women
    Breast cancer

    Breast Cancer Is More Fatal in Men Than Women

    Men have higher death rates than women across all stages of breast cancer, study findings reported in JAMA Oncology show. In the study, five-year overall survival after a breast cancer diagnosis was 77.6% for men and 86.4% for women.

    January 15, 2020
    Multigene Testing Is Cost Effective for All Women With Breast Cancer
    Genetics & genomics

    Multigene Testing Is Cost Effective for All Women With Breast Cancer

    According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.

    December 20, 2019
    Research Guides the Transition of PEP Resources to ONS Guidelines
    Research

    Research Guides the Transition of PEP Resources to ONS Guidelines

    Lymphedema is one of the most common treatment side effects in patients with breast cancer. Estimates suggest that approximately 40% of all breast cancer survivors are at risk to develop lymphedema at some point in their lives. But as far back as 1998 and even before, some healthcare experts were predicting that lymphedema would be eliminated as a side effect from breast cancer treatment. Twenty-one years later, it’s still prevalent among breast cancer survivors, requiring careful management recommendations from oncology nurses to help patients live with this chronic issue.

    December 10, 2019
    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer
    Breast cancer

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

    Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.

    December 04, 2019
    USPSTF Updates Recommendations on Breast Cancer Prevention
    Research

    USPSTF Updates Recommendations on Breast Cancer Prevention

    Certain groups of women who are at increased risk for carrying BRCA1 or BRCA2 genes should be assessed for the need for genetic testing, and women at increased risk for breast cancer and low risk of adverse events should be offered risk-reducing medications, the U.S. Preventive Services Task Force (USPSTF) recommended.

    November 06, 2019
    Getting the Right Treatment at the Right Time Reduces Inequities in Breast Cancer Survival
    Cancer health disparities

    Getting the Right Treatment at the Right Time Reduces Inequities in Breast Cancer Survival

    Although death rates from breast cancer have been falling, the trend has not been equal among all women. Looking at breast cancer survival on a population level can tell us how effective our public health and healthcare systems are at early diagnosis, delivery of evidence-based treatment, and management of follow-up care.

    October 08, 2019
    Pediatric Cancer Survivors Have Higher Mortality After Adult Breast Cancer Diagnosis
    Survivorship

    Pediatric Cancer Survivors Have Higher Mortality After Adult Breast Cancer Diagnosis

    Women who survived pediatric cancer but developed breast cancer as an adult are more than twice as likely to die prematurely, mostly from comorbid conditions, according to results of a study published in the Journal of Clinical Oncology.

    October 02, 2019
    Wasserman Schultz, Brooks Introduce EARLY Act for Breast Cancer Awareness
    Health Policy

    Wasserman Schultz, Brooks Introduce EARLY Act for Breast Cancer Awareness

    Health care is the top domestic policy issue for Americans, but with so many different ideas to make the healthcare system more accessible and affordable, the issue is becoming increasingly complex. Because of its far-reaching impact, health care is often a politically charged topic and little change has yet been seen on a legislative level.

    August 19, 2019
    Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer
    Treatments

    Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer

    The U.S. Food and Drug Administration (FDA) first approved atezolizumab (Tecentriq®) in 2016, but it received additional approvals when used in combination treatments for locally advanced or metastatic triple negative breast cancer (TNBC) and small cell lung cancer (SCLC) in March 2019.

    July 23, 2019
    Test Predicts Which Women Will Benefit From Chemo for Breast Cancer
    Breast cancer

    Test Predicts Which Women Will Benefit From Chemo for Breast Cancer

    A prediction test accurately identifies which women with estrogen receptor (ER)-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy, according to the results of a study published in Breast Cancer Research and Treatment. 
     

    July 03, 2019
    FDA Links Breast Implants to Increased ALCL Risk
    U.S. Food and Drug Administration (FDA)

    FDA Links Breast Implants to Increased ALCL Risk

    People with breast implants have a risk of developing breast implant-associated anaplastic large cell lymphoma (ALCL), the U.S. Food and Drug Administration (FDA) announced in April 2019. Typically the cancer is limited to the scar tissue and fluid near an implant, but some patients experience spread throughout the body. The risk increases with textured implants in particular.

    June 12, 2019
    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲